MBOTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Microbot Medical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.95+0.00 (+0.29%)
Close on Oct 19, 2026
- Market cap
- $63.99M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -1184.2% | -32.8% | -32.4% | |
| Return on assets | -495.9% | -28.9% | -30.0% | |
| Current ratio | 4.23 | 18.78 | 23.33 | |
| Interest coverage | -28.9× | – | – | |
| Diluted shares | 1M | 7M | 46M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Microbot Medical generated $51.31M from operations and spent $271.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$51.31M
Used
$271.00K
Capital expenditure$271.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$13.14M
- Cash generatingOperating cash flow above zero-$13.05M
- Return on assets improvedROA up on the prior year-137.4% → -217.9%
- Earnings backed by cashOperating cash flow above net income-$13.05M vs -$13.14M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.37 → 23.33
- No dilutionShare count did not rise16M → 46M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –